Cargando…
Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma
Monoclonal antibodies (mAbs) directed against antigen-specific of multiple myeloma (MM) cells have Fc-dependent immune effector mechanisms, such as complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP), but the c...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297441/ https://www.ncbi.nlm.nih.gov/pubmed/34307150 http://dx.doi.org/10.3389/fonc.2021.684561 |
_version_ | 1783725861712691200 |
---|---|
author | Romano, Alessandra Storti, Paola Marchica, Valentina Scandura, Grazia Notarfranchi, Laura Craviotto, Luisa Di Raimondo, Francesco Giuliani, Nicola |
author_facet | Romano, Alessandra Storti, Paola Marchica, Valentina Scandura, Grazia Notarfranchi, Laura Craviotto, Luisa Di Raimondo, Francesco Giuliani, Nicola |
author_sort | Romano, Alessandra |
collection | PubMed |
description | Monoclonal antibodies (mAbs) directed against antigen-specific of multiple myeloma (MM) cells have Fc-dependent immune effector mechanisms, such as complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP), but the choice of the antigen is crucial for the development of effective immuno-therapy in MM. Recently new immunotherapeutic options in MM patients have been developed against different myeloma-related antigens as drug conjugate-antibody, bispecific T-cell engagers (BiTEs) and chimeric antigen receptor (CAR)-T cells. In this review, we will highlight the mechanism of action of immuno-therapy currently available in clinical practice to target CD38, SLAMF7, and BCMA, focusing on the biological role of the targets and on mechanisms of actions of the different immunotherapeutic approaches underlying their advantages and disadvantages with critical review of the literature data. |
format | Online Article Text |
id | pubmed-8297441 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82974412021-07-23 Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma Romano, Alessandra Storti, Paola Marchica, Valentina Scandura, Grazia Notarfranchi, Laura Craviotto, Luisa Di Raimondo, Francesco Giuliani, Nicola Front Oncol Oncology Monoclonal antibodies (mAbs) directed against antigen-specific of multiple myeloma (MM) cells have Fc-dependent immune effector mechanisms, such as complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP), but the choice of the antigen is crucial for the development of effective immuno-therapy in MM. Recently new immunotherapeutic options in MM patients have been developed against different myeloma-related antigens as drug conjugate-antibody, bispecific T-cell engagers (BiTEs) and chimeric antigen receptor (CAR)-T cells. In this review, we will highlight the mechanism of action of immuno-therapy currently available in clinical practice to target CD38, SLAMF7, and BCMA, focusing on the biological role of the targets and on mechanisms of actions of the different immunotherapeutic approaches underlying their advantages and disadvantages with critical review of the literature data. Frontiers Media S.A. 2021-07-08 /pmc/articles/PMC8297441/ /pubmed/34307150 http://dx.doi.org/10.3389/fonc.2021.684561 Text en Copyright © 2021 Romano, Storti, Marchica, Scandura, Notarfranchi, Craviotto, Di Raimondo and Giuliani https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Romano, Alessandra Storti, Paola Marchica, Valentina Scandura, Grazia Notarfranchi, Laura Craviotto, Luisa Di Raimondo, Francesco Giuliani, Nicola Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma |
title | Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma |
title_full | Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma |
title_fullStr | Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma |
title_full_unstemmed | Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma |
title_short | Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma |
title_sort | mechanisms of action of the new antibodies in use in multiple myeloma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297441/ https://www.ncbi.nlm.nih.gov/pubmed/34307150 http://dx.doi.org/10.3389/fonc.2021.684561 |
work_keys_str_mv | AT romanoalessandra mechanismsofactionofthenewantibodiesinuseinmultiplemyeloma AT stortipaola mechanismsofactionofthenewantibodiesinuseinmultiplemyeloma AT marchicavalentina mechanismsofactionofthenewantibodiesinuseinmultiplemyeloma AT scanduragrazia mechanismsofactionofthenewantibodiesinuseinmultiplemyeloma AT notarfranchilaura mechanismsofactionofthenewantibodiesinuseinmultiplemyeloma AT craviottoluisa mechanismsofactionofthenewantibodiesinuseinmultiplemyeloma AT diraimondofrancesco mechanismsofactionofthenewantibodiesinuseinmultiplemyeloma AT giulianinicola mechanismsofactionofthenewantibodiesinuseinmultiplemyeloma |